Efficacy of a novel ferrocenyl diaryl butene citrate compound as a biocide for preventing healthcare-associated infections. Issue 5 (10th March 2016)

• Record Type: Journal Article
• Authors: El Arbi, Mehdi; Jalléli, Karim; Trigui, Fatma; Pigeon, Pascal; Görmen, Meral; Top, Siden; Aifa, Sami; Fliss, Ismail; Jaouen, Gérard; Hammami, Riadh
• Is Part Of: MedChemComm. Volume 7:Issue 5(2016:May)
• Page Start: 948
• Page End: 954
• Publication Date: 2016-03-10
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c5md00568j
• Languages: English
• ISSNs: 2040-2503

Abstract

Abstract : The antiseptic and disinfectant potential of a formulation containing a tamoxifen analogue was assessed according to European standards and pharmacopeia in comparison with a commercial antiseptic product. Abstract : The antiseptic and disinfectant potential of a formulation containing the tamoxifen analogue 1, 1-bis[4-(3-dimethylaminopropoxy)phenyl]-2-ferrocenyl-but-1-ene citrate was assessed according to European standards and pharmacopeia in comparison with a commercial antiseptic product containing hexamidine diisethionate, chlorhexidine digluconate and chlorocresol as active ingredients. The formulation met the phase 1 requirement of reducing by 5 cycles the counts of microorganisms frequently involved in healthcare-associated infections, namely Escherichia coli ATCC 10536, Pseudomonas aeruginosa ATCC 15442, Staphylococcus aureus ATCC 6538, Enterococcus hirae ATCC 10541 and Candida albicans ATCC 10231. It also killed a clinical isolate of Acinetobacter baumannii which is highly resistant to antibiotics and antiseptics. In phase 2/step 2 tests, it reduced the counts of E. coli ATCC 10536 by 4 log cycles within 60 seconds on hands (standard EN 1499). The novel formula is a potent biocide, and this demonstration could lead to the development of a new commercial antiseptic.